The terminology describing extracellular vesicles (EVs) has been changed substantially as understanding of EV biology has increased, and the definitions of 'micro vesicles' , 'exosomes' and 'microparticles' , which were used interchangeably in the past, have been redefined [1] [2] [3] [4] [5] . Exosomes are homogeneous vesicles (50-150 nm) that originate from multivesicular bodies (MVBs) and repre sent a discrete subpopulation of the greater family of EVs 2,6,7 (FIG. 1) . On the basis of mode of biogenesis and surface protein expression, exosomes (50-150 nm in diameter) are differentiated from other types of EVs such as micro vesicles (100-1,000 nm) and apoptotic bodies (500-2,000 nm) 8 . In contrast to exosomes, micro vesicles are directly formed and released from the plasma mem brane. Several proteins, such as flotillin 1, heat shock 70 kDa proteins or major histo compatibility complex (MHC) class I and class II proteins, were historically used as exclusive exosomal subfraction biomarkers 9 . However, new reports have suggested the presence of some of those markers in other subpopulations of EVs 9 . With the rapid advances in '-omics' technology, specific molecular patterns will further our knowledge about dif ferent types of vesicles and improve their classification. However, inconsistencies in the isolation methods and mixed methodology and terminology used in the past make the distinction of subtypes of those vesicles diffi cult. We will refer to both microvesicles and exosomes using the collective term 'EVs' .
. Exosomes are homogeneous vesicles (50-150 nm) that originate from multivesicular bodies (MVBs) and repre sent a discrete subpopulation of the greater family of EVs 2, 6, 7 (FIG. 1) . On the basis of mode of biogenesis and surface protein expression, exosomes (50-150 nm in diameter) are differentiated from other types of EVs such as micro vesicles (100-1,000 nm) and apoptotic bodies (500-2,000 nm) 8 . In contrast to exosomes, micro vesicles are directly formed and released from the plasma mem brane. Several proteins, such as flotillin 1, heat shock 70 kDa proteins or major histo compatibility complex (MHC) class I and class II proteins, were historically used as exclusive exosomal subfraction biomarkers 9 . However, new reports have suggested the presence of some of those markers in other subpopulations of EVs 9 . With the rapid advances in '-omics' technology, specific molecular patterns will further our knowledge about dif ferent types of vesicles and improve their classification. However, inconsistencies in the isolation methods and mixed methodology and terminology used in the past make the distinction of subtypes of those vesicles diffi cult. We will refer to both microvesicles and exosomes using the collective term 'EVs' .
The cargo of EVs contains proteins, lipids and nucleic acid, coated with a lipid bilayer (FIG. 2) . EVs are secreted into the extracellular space, and thereby the circulation, by various cell types of the liver (discussed later) [10] [11] [12] . The EV cargo represents a snapshot of the parental cell at the time of release and can change depending on the stimulation status and/or differentiation stage of the cell [13] [14] [15] . This observation suggests that EV release and content are dynamic, providing opportunities and chal lenges in the evaluation of EVs as biomarkers. EVs con tain different macromolecules, including nucleic acids, proteins and lipids [16] [17] [18] [19] . The composition of EVs might not be identical to the content of the cytosol of the cell of origin, suggesting active sorting of biomolecules into EVs 4, 15 . In this Review, we focus on EVs and their role in physiology and the pathophysiology of liver disease and we discuss their utility in biomarker discovery and their therapeutic potential. Although EVs were consid ered initially as cellular byproducts with insignificant biological importance, studies published in the past few years have identified EVs as conveyors of intercellular communication 16, 20, 21 . Liver and other tissues shed EVs into the biological fluid and their abundance makes them compelling entities for a socalled liquid biopsy, or a 'fluidome' .
Liver as the source of EVs
Although the detection of EV production in vivo at the tissue level awaits development of new technolo gies, the in vivo presence of circulating EVs indicates that they are produced in specific tissues and cells 22 . Most cell types in the liver have been shown to produce EVs under in vitro conditions, including hepato cytes, cholangiocytes, hepatic stellate cells (HSCs), sinu soidal endothelial cells (SECs), Kupffer cells and other immune cell populations such as macrophages response to cellular stimulation and under different disease conditions 16, 30 . Proteomic analysis revealed the presence of ~251 proteins in EVs derived from pri mary rat hepatocytes 31 . In addition to transmembrane proteins, such as tetraspanins described in EVs from other cell types (including CD63, CD81 and CD82) and the asialoglycoprotein receptor 1 (ASGR1), enrich ment of hepatocytespecific receptors was also found in hepatocyte derived EVs 31 . The hepatocyte derived EV cargo included proteins involved in the endosomal pathway and detoxification, cytosolic proteins includ ing cytochromes, as well as secreted proteins such as coagulation related proteins and apolipoproteins 31 . These findings suggest that the protein and nucleic acid composition of cellderived EVs can change in response to cellular stress or other stimulations, raising the ques tion of whether EVs released under cell or organ stress and disease conditions could have a different biological role compared with normal homeostasis, or could serve as biomarkers 16, 31 . Microvesicles and exosomes derived from rat bile were found to attach to cholangiocyte cilia, resulting in a decrease in the ratio of phosphorylated extra cellular signalregulated kinase (ERK)1 and ERK2 to total ERK1 and ERK2, and increased miR15A expression and reduced cholangiocyte proliferation 32 . In chickens, bili ary EVs enhanced CD4 + and CD8 + Tcell proliferation and macrophage activation in the liver, and inhibited avian leukosis virus replication in a chicken fibroblast cell line (DF1 cells) 33 . 34 . In patients with cirrhosis, plasma hepatocyte derived EVs contained elevated levels of cytokeratin18 compared with healthy individuals. The severity of cirrho sis was found to be correlated with the levels of leuko endothelialderived and hepatocyte derived EVs. Those EVs had functional effects, as they impaired contraction of vessels in response to phenyl ephrine in a manner dependent on prostaglandin G/H syn thase 1 (also known as cyclooxygenase 1) in rat aortic rings 34 . EVs (enriched in the exosome fraction) derived from SECs were found to modulate HSC func tion. Internalization of SECderived EVs triggered [36] [37] [38] [39] . In vitro studies indicate that immunecellderived EVs provide communication between the different cell types in the liver, both within the immune cell compartment and between immune and parenchymal cells. However, the full functional potential of liver and hepatocytederived EVs is yet to be fully understood. In mouse models of ischaemia-reperfusion injury or partial hepatectomy, hepatocytederived EVs (and not EVs from other liver cell types) were shown to mediate liver repair and regener ation by transferring ceramidase and sphingo sine kinase 2 that increases sphingosine1phosphate prod uction in target hepatocytes 40 . In another study, EVs enriched with microRNA (miR)122 derived from hepatocytes after alcohol exposure were taken up by macrophages, resulting in transfer of hepatocyte derived miR122 (REF. 16) (FIG. 4) . Although unstimulated macro phages have undetectable levels of miR122, miR122 transferred by EVs sensitized macrophages to increased TNF production in response to lipopolysaccharide (LPS) stimulation 16 . Macrophagetomacrophage communi cation was also found via exosomal transfer of miR27a after alcohol exposure, resulting in preferential induc tion of the M2, or alternatively activated, macrophage phenotype 14 . Thus, these findings demonstrate that EVs released by one cell type are taken up by other cells and thereby mediate transfer of biomolecules, such as miRs, that alter functions of recipient cells. These observations open a new paradigm in intercellular communication in the liver, regulated by EVs.
Liver as the target of EVs
Currently the biogenesis and biodistribution of EVs is only partially understood. That EVs can interact with different cells in the liver through specific receptors and cellular uptake is already known. For example, EVs derived from hepatocytes can modulate function and activation of liver macrophages or mediate liver regener ation 4 . Specific EV ligands, such as tetraspanins or MHCI and MHCII, can interact with the target cells by different signalling pathways 41 . EV uptake by most cell types is via endocytosis, including clathrindependent endocytosis and clathrinindependent pathways, such as caveolinmediated uptake, phagocytosis, macropino cytosis and lipidraftmediated internalization 42 . Lipid and protein interactions facilitate EV uptake, and tetra spannins, integrins, immunoglobulins, peptidoglycans and lectins all contribute to EV uptake by target cells 42 . Several studies have demonstrated that the liver is an active site of EV uptake. Imai et al. 43 showed that PKH26labelled exosomes derived from the mouse melanoma cell line B16BL6 were taken up by macro phages in the liver and spleen, but not in the lung, after intravenous administration. Bala et al. 44, 45 showed that 44, 45 . The functional capacity of EVderived miR155 was indicated by increased proinflammatory cytokine induc tion in mir-155knockout mice after exosomal transfer of miR155 (REFS 44, 45) . Exosomederived miR146a and miR155 were shown in another study to modulate inflammatory responses to endotoxin in mice 20 .
Hepatocytederived EVs can also mediate liver repair and regeneration in ischaemia-reperfusion injury and after partial hepatectomy 40 . Interestingly, EVs derived from hepatocytes, and not other liver cell types, induced a dosedependent proliferation of hepatocytes in vitro. Hepatocyte EVs taken up by target hepatocytes trans ferred neutral ceramidase and sphingosine kinase 2, causing increased synthesis of sphingosine1 phosphate in this model. Consistent with this mechanistic explan ation, ablation of exosomal sphingosine kinase 2 prevented the proliferative effect of exosomes 40 . 46, 47 . Although new therapies for HCV eradi cation are increasingly efficacious, exosome mediated HCV infection is considered an alternative route of HCV transmission that can have an effect on treatment with oral antiviral therapies 46 .
EVs in viral hepatitis
EVs from the cell culture supernatant of cells infected with GB virus C (GBVC, a human virus of the Flaviviridae family related to HCV) or serum from individuals with GBVC infection were shown to inhibit Tcellreceptor signalling, which was associated with the GBVC envelope 2 protein found in EVs 48 . GBV found in the EVs was functional and transmitted viral RNA to peripheral blood mononuclear cells in vitro, resulting in productive infection 49 . These observations highlight the potential importance of EVs in viral hepatitis infection and transmission.
Patients with chronic HCV infection showed increased platelet activation and a higher percentage of plateletderived EVs in the circulation than patients with chronic HBV infection 50 . The percentage of platelet derived EVs in these individuals correlated with levels of liver fibrosis markers, such as serum hyaluronate and Nterminal propeptide of type III procollagen, indi cating a possible role for platelet activation in increasing EV numbers and promoting liver fibrosis, a concept that deserves further investigation 50 . In a study published in 2013, Li et al. 51 reported that in vitro IFNα treatment induced the transfer of HBV resistance from nonpermissive liver nonparenchymal cells to permissive hepatocytes via EVs containing anti viral proteins. HBV nucleic acids and proteins have also been found in EVs in the sera of patients with chronic HBV infection 52 . These EVs interacted with natural killer cells and impaired their function, resulting in decreased IFNγ production and reduced expression of ATPdependent RNA helicase DDX58 (also known as retinoic acidinducible gene 1 protein; RIGI), an intra cellular viral sensing receptor. In HCV infection, HCV induced monocyte differentiation into M2 macrophages, which in turn promoted HSC activation; this HSC activ ation effect was reproduced by EVs derived from HCV infected hepatocytes 53 . Collectively, these results suggest that EVs have an important role in viral transmission of both HCV and HBV, as well as in undermining innate immune responses in chronic viral hepatitis.
EVs in steatohepatitis
In experimental steatohepatitis induced in mice by cholinedeficient, lamino aciddefined (CDAA) and highfat diets, the levels of circulating EVs, both exosomes and microvesicles, were increased compared with mice fed control diets 54 . Proteomic analysis of the EVs revealed differences in the cargo between mice with NAFLD and controls. The authors proposed that the liver was a source of the EVs on the basis of their con tent of miR122 and miR192, which are predominantly and abundantly expressed in hepatocytes 54 . Lipotoxic activation of hepatocytes with free fatty acids was also shown to induce release of EVs enriched in ceramide, and these vesicles induced macrophages chemotaxis, suggesting a mechanism for NASHrelated inflam mation 55 . Consistently, highfat diet in rats increased the number of circulating EVs that promoted inflam mation 56 . Increased quantities of hepatocyte derived EVs were detected in the blood of mice with high fatdietinduced steatohepatitis, and the increase in circu lating EVs correlated with disease severity. Those vesicles were internalized into human umbilical vein endothelial cells (HUVECs) in vitro by a mechanism dependent on pantetheinase (also known as Vanin1), and promoted angiogenesis and induced liver damage in steatohepatitis. Hepatocyteconditioned media in which the EVs were removed by ultra centrifugation lacked proangiogenic activity 57 . In another report, patients with NAFLD showed increased numbers of EVs originating from invariant natural killer T cells and CD14 + macro phages and monocytes, which have a pathogenic role in disease progression 58 . The number of EVs corre lated well with plasma levels of alanine transaminase (ALT) and the severity of disease as assessed by histo logy 58 . In the context of NASH, it has been shown that lipids induce release of EVs from primary human and mouse hepato cytes through a death receptor 5 (also known as tumour necrosis factor receptor superfamily member 10B) signalling pathway, which then activate an inflamma tory phenotype in macrophages 59 . Consistent with this observation, mixed lineage kinase 3 (MLK3, also known as mitogenactivated protein kinase kinase kinase 11) induces the release of CXC motif chemo kine 10 (CXCL10)laden EVs from hepatocytes treated with lipotoxic lipids, which induce macrophage chemo taxis 60 . MLK3deficient mice fed a NASHinducing diet showed diminished number of total plasma EVs and EVs containing CXCL10 compared with wildtype mice 60 .
In patients with alcoholic hepatitis, the number of circulating EVs, particularly exosomes, was found to be higher than in healthy individuals 16, 61 . Likewise, in a mouse model of alcoholinduced steatohepatitis, the number of circulating EVs was increased compared with the pairfed controls, and these EVs were enriched in miR122, miR192 and miR30 (REF. 62 ). The clinical relevance of these findings was confirmed in patients with alcoholic hepatitis, in which increased numbers of circulating EVs containing elevated levels of miR122, miR192 and miR309 were found 62 . Acute alcohol binge drinking also increased the number of circulating EVs in healthy volunteers, and these EVs were enriched in miR122 an miR155 (REF. 16 ). In vitro, alcohol treatment induced the release of EVs in hepatoma cells and in pri mary mouse and human hepatocytes 16 . Alcohol treat ment also induced EV release in macrophages, suggesting that EV production in alcoholic liver disease occurs in both parenchymal and immune cells 14 . In alcoholic liver disease, hepatocytederived EVs enriched in miR122 are taken up by macrophages, resulting in functional changes and sensitization of these cells to LPSinduced proinflammatory responses 16 . These observations sug gest an important and unexpected role for hepatocyte derived EVs in modulation of inflammation in alcoholic diver disease (FIG. 4) . A study published in 2016 by Verma et al. 61 showed that hepatocytes release CD40ligand containing EVs in a caspasedependent manner in response to alcohol exposure, and that these EVs promote macrophage activation and contribute to the inflamma tory profile of alcoholic hepatitis. Together, these obser vations suggest dynamic, EVmediated communication between hepatocytes and macrophages in the liver.
EVs in drug-induced liver injury
Circulating EVs are now in focus as potential bio markers in druginduced liver injury (DILI) 63 . In a mouse model of paracetamolinduced liver injury, increased serum miR122 levels were found both in the exosomal rich and proteinrich serum fractions 64 . In a rat model of paracetamol induced DILI, increased numbers of cir culating EVs were found and these EVs showed elevated levels of miR122 and albumin mRNA 63 . Increased serum miR122 levels were also found early in patients with paracetamolrelated liver injury and the serum miR profile in paracetamolinduced DILI showed some specifi city compared with ischaemic hepatitis 65 . In another study, proteomic analysis of EVs isolated from the sera of rats after dgalactosamine or LPS administration showed a characteristic protein compo sition that corre lated with liver toxicity, indicating the potential of EV protein cargo as a biomarker in DILI 24 .
EVs in liver fibrosis
A hallmark of liver fibrosis is activation of HSCs. A study by Chen et al. 26 showed that quiescent HSCs produce EVs containing high levels of twistrelated protein 1 (TWIST1), which drives miR214 expression and results in decreased mRNA levels of connective tissue growth factor (CCN2). Exosomal TWIST1 was shown to shuttle between activated and quiescent HSCs, and hepatocytederived EVs also regulated miR214 expres sion in HSCs, demonstrating a complex intercellular interaction involving EVs and miRs in liver fibrosis 26 . In another study, EVs derived from endothelial cells were internalized by HSCs, resulting in sphingosine1 phosphatedependent HSC activation and promotion of liver fibrosis 35 .
EVs in liver cancer
Cancer cells, including hepatocellular cancer (HCC) cell lines, secrete increased numbers of EVs compared with noncancer cells, and these EVs have pro metastatic effects 66, 67 . EV release from HCC cell lines was also increased after anticancer drug exposure and those EVs could activate natural killer cells to elicit antitumour immunity 68 . This study also found that EVs containing HSPs HSP60, HSP70 and HSP90 stimulate cyto toxicity and granzyme B production in natural killer cells 68 . Furthermore, stemcellderived EVs (enriched for the microvesicle fraction) inhibited HCC growth and survival in a mouse model of the disease 28 . Growth of HepG2 hepatoma cells was inhibited both in vitro and in vivo by addition of EVs derived from human bone marrow mesenchymal stem cells (MSCs); however, the mechanism by which MSCderived EVs exert this effect is yet to be understood 69 . EVassociated RNA from colorectal cancer cells is delivered to hepatoma cells and lung cell lines in vitro, and this observation has raised the possibility of cancer metastasis via exosomemediated nucleic acid deliv ery 70 . EVs derived from pancreatic cancer promote liver metastasis by initiating premetastatic niche formation that involves uptake of exosomederived factors, such as macrophage migration inhibitory factor (MIF), causing Kupffer cell and HSC activation. This process generated a fibrotic microenvironment with immune cell infiltration that promoted metastasis 71 . Notably, EVs derived from a highly liver metastatic colorectal cancer cell line (HT29) increased the metastatic tumour burden and extension of Caco2 colorectal cancer cells in mouse liver; Caco2 cells usually demonstrate poor liver metastatic poten tial 72 . Wang et al. 72 suggested that HT29 cancer cells pro mote colorectal cancer metastasis by recruiting CXC chemokine receptor type 4 (CXCR4)expressing stromal cells, which are permissive to metastatic niche formation.
EVs as novel biomarkers
Biomarker discovery represents an approach for the early detection, monitoring and evaluation of treatment response in various liver diseases. Different definitions of biomarkers have been reviewed in BOX 1. Although liver biopsy is still the goldstandard approach for diagnosis, staging and monitoring of liver disease, there is great demand for noninvasive markers, such as bio markers and liquid biopsy, which could mitigate the need for the invasive liver biopsy 62, 73, 74 . Currently, the bloodbased Alcohol can activate cell regulatory networks controlling inflammation and cell death including caspases, which can lead to activation of apoptosis pathways and increased exosome production. miR-122 sensitizes macrophages to lipopolysaccharide (LPS) stimulation and induces an augmented proinflammatory profile. Alcohol increases secretion of EVs, which are taken up by naive monocytes and induce an M2 macrophage phenotype, as indicated by M2 surface markers (CD68, CD163 and CD206) and increased levels of IL-10 and transforming growth factor-β (TGFβ). EVs derived from hepatocytes contain CD40L, and after being taken up by monocytes these EVs promote macrophage activation, contributing to inflammation in alcoholic hepatitis. ER, endoplasmic reticulum; MVB, multivesicular body; TLR4, Toll-like receptor 4. . Using EVs as biomarkers potentially provides new dimensions in nucleicacid based and proteinbased diagnostics. First, due to membrane coating, EVs protect their protein and nucleic acid cargo from degradation 79 , an attractive property for use in diagnosis. Second, EVs are enriched with highly selected markers during exo somal sorting, which otherwise constitute only a very small proportion (<0.01%) of the total proteome of body fluids 80 . This enrichment of diagnostic molecules in EVs facilitates identification of low abundance nucleic acid or protein biomarkers that normally would go undetected. In circulating EVs in healthy individuals, ~66 proteins were identified, most of which were involved in vesicu lar trafficking pathways 19, 81 . Third, confining biomarker discovery to EVs, as opposed to total plasma or serum, will decrease the complexity of the assay 24 . Fourth, the number of EVs reflects the metabolism of cells in tissues and analysis of their cargo might provide direct informa tion on disease progression, recovery and drug response. As such, the discovery of novel candidate nucleic acids and protein biomarkers in EVs could open new avenues of investigation in assessing disease progression, recov ery and therapy response. Specific protein contents or nucleic acid contents of EVs have been suggested as bio markers for detection of different liver disease (TABLE 1) , yet none of the suggested biomarkers has been validated in independent studies, and none of the studies of these biomarkers in liver disease has adequately established sensitivity and specificity. (TABLE 1) . Fulllength soluble receptortype tyrosineprotein phosphatase γ ( sPTPRG) isoforms associated with EVs have been identi fied as a biomarker for liver injury in human and mouse plasma 82 . A positive correlation between high plasma levels of sPTPRG and liver damage was observed in human plasma samples with low (ALT <40 U/ml) or increased (ALT >450 U/ml) ALT levels 82 . EVs were also identified as conveyors of connective tissue growth factor (CTGF) as they transferred CTGF between HSCs and subsequently amplified fibrogenic signalling. This finding suggests that EVs containing CTGF could have utility as a non invasive biomarker to assess hepatic fibro sis 83 . In another study, soluble CD81 was increased in the serum EV fraction in patients with chronic hepatitis C compared with healthy individuals and patients who had recovered, and EVassociated soluble CD81 levels were associated with plasma ALT levels and severe forms of liver fibrosis 84 . In a proteomic study on EVs derived from cultured hepatocytes and EVs from the sera of liverinjured mice, increased levels of some liverspecific proteins such as the enzymes carbamoyl phosphate synthase 1 (CPS1), Sadenosylmethionine synthase 1 (MAT), and catechol Omethyltransferase (COMT) were observed 24 . In agree ment with these results, upregulation of MAT enzyme levels have been previously shown to be required for the proper liver regeneration in hepatectomized mice 24, 85 . Circulating EVs enriched in liverorigin proteins were isolated from the plasma of patients with HCC using affinity isolation specific to the monoclonal antibody hepatocyte paraffin 1 (REF. 86 ). The levels of these liver specific circulating EVs were increased in patients with HCC and correlate well with the size of the liver tumours 86 . In another study on urine samples in an acute liver injury animal model, a set of differentially expressed proteins including CD26, CD81, SLC3A1 and CD10 were identified and proposed as biomarkers of liver disease. Notably, dgalactosamine treatment, which generates acute liver injury, results in a severe reduction in some proteins that normally are clearly detected in urinary vesicles in rats, suggesting that protein composition of urinary EVs can reflect liver damage 87 .
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EV proteins as potential biomarkers of liver disease. Several potential proteinbased EV biomarkers have been introduced for liver diseases
Nucleic acid cargo of EVs as biomarkers in liver diseases.
The cargo of EVs includes both proteins and nucleic acid; however, most studies to date have focused on characterizing nucleic acid composition. EVassociated nucleic acids, especially miRs, have generated interest as biomarkers for various diseases (TABLE 1) . Several miRs have been introduced as potential biomarkers of HCC. miR718 showed decreased expression in serum EVs of patients with HCC with recurrence after liver transplanta tion compared with those without recurrence. Decreased levels of miR718 were associated with the aggressive ness of HCC tumours in a separate cohort of patients 66 .
In another study, miR21 was shown to be elevated in the serum EV fraction of patients with HCC compared with the EVdepleted serum fraction, and the level of serum exosomal miR21 was higher in patients with HCC than in healthy individuals and patients with chronic hepati tis B. High levels of miR21 expression were correlated with cirrhosis and advanced tumour stage. EVassociated miR21 was reported to have higher diagnostic sensitivity and accuracy than miR21 in whole serum 88 . In a 2012 study, our group showed that increased serum and plasma levels of miR122 correlated with serum ALT level increases in different liver damage models induced by alcohol, paracetamol or Tolllike receptor (TLR)9 ligands (CpG dinucleotides and LPS) 64 . Levels of both miR155 and miR146a, referred to as inflammamiRs 89 , were increased in the serum and plasma of mice with inflammationrelated liver diseases such as alcoholinduced liver injury or after CpG and LPS admin istration 64 . In models of liver injury mediated by alcohol or proinflammatory TLR9 and TLR4 signalling, serum and plasma miR122 and miR155 were predomin antly associated with the EVrich fraction in mice; by contrast, these miRs were enriched in the proteinrich fraction in DILI 64 . The number of circulating EVs was also increased in patients with acute alcoholic hepatitis compared with healthy individuals 16 . Increased numbers of EVs and elevated levels of miR122 were also found in EVs isolated from the sera of patients with alcoholic hepatitis or healthy individ uals after binge drinking alcohol, compared with healthy individuals and each individual's own established base line levels, respectively 16, 62 . In addition to miR122, levels of miR192 and miR30a were increased in EVs isolated from the sera of mice chronically fed ethanol or patients with alcoholic hepatitis 62 . Of these miRs, miR192 showed the highest diagnostic accuracy of alcoholic hepatitis, identified by an area under the curve (AUC) of 0.96 (P <0.001). miR122 and miR30a demonstrated an AUC of 0.92 (P <0.001) and 0.85 (P <0.05), respectively 62 .
Box 2 | Future research directions for extracellular vesicles
Common definitions of extracellular vesicles (EVs) types, specific isolation techniques and characterization of EVs, exosomes and microvesicles have led to greatly expanding research into EVs in the past few years. Application of '-omics' technologies such as proteomics, lipidomics and transcriptomics have advanced EV studies to promise new understanding of liver and biliary diseases. The comprehensive understanding of EVs and their subtypes and cargoes in liver diseases should lead to the development of EV-based biomarkers (liquid biopsy) to aid disease diagnosis. EVs should be exploited in assessment of disease prognosis, stratification of patients and monitoring of disease progression and/or treatment response in the context of personalized medicine. Future studies for EV-based biomarker discovery should use multi-analytical, systems biology approaches in independent large cohorts, with comparison against current diagnostic methods and biomarkers to identify molecular signatures associated with different liver diseases. Such discoveries should pinpoint potential targets of pharmacological intervention in liver disease. Given the complexity of cells that have roles in the initiation and progression of liver disease, a comprehensive reference profile for cell-specific and tissue-specific EVs and their molecular signatures should be produced. On the basis of studies indicating that exosomes released from one cell type in the liver can modulate the function and/or reprogramme other cell types within the liver, additional exploration of EVs in intercellular communication and disease progression is warranted. Finally, the stability and easy cellular uptake of exosomes makes them attractive for their potential as delivery vehicles in therapeutic interventions. Many challenges remain, including the inability to track EV production and distribution in vivo, the need for better markers to assess the cell-of-origin for EVs and the requirement for standardization in diagnostic and therapeutic applications of EVs.
Research areas for the roles of EVs in liver disease
Discovery of EV biomarkers. Despite EVs holding promise for new biomarker discovery, large studies on the diagnostic, prognostic and predictive value of EV biomarkers in different liver diseases are lacking
. Although EVs have been shown to associate with known markers of pathogenesis, association of EVs with patient oriented outcomes such as progno sis and response to the treatment are yet to be evalu ated. Moreover, indepen dent comprehensive studies in wellcharacterized patient popu lations are needed to assess the sensitivity and specifi city of EV bio markers in relation to clinical outcomes. These studies will aid discoveries of EV biomarkers in liver diseases that should not be limited to miRs, and will probably involve other nucleic acids (for example, long noncoding RNAs ( lncRNAs)), proteins and lipid markers. Additional limitations include the requirement to standardize EV, exosome and microvesicle isolation procedures from various biofluids. Although there has been substantial progress in this area in the past 5 years through the NIH Extracellular RNA Communication Consortium and the International Society for Extracellular Vesicles, challenges regarding isolation, preanalytical and post analytical aspects of EV biomarker use still remain. Although different isolation techniques are available and optimization of these techniques was the subject of rigorous research, each technique has its own advan tages and limitations and the proper isolation method or combination of methods must be chosen on the basis of the research question, quantity and quality and level of purity needed. 90 reported that freezing at −20 °C led to a major loss in urinary EVs compared with storing at −80 °C. Increasing time between venipuncture and centri fugation has also been reported to induce degradation and rupture of EVs 91 . Another example of a preanalytical parameter that should be taken into account is the effect of circadian rhythm on EV cargos. For instance, expression of sol ute carrier family 12 member 3 (also known as NaCl cotransporter) and prostasin in urinary EVs has been reported to be affected by circadian rhythm 92 .
EVs as therapeutic tools in liver diseases
The use of EVs, especially the exosome sub population, as vehicles for RNA interference (RNAi) and drug deliv ery has generated considerable attention in the scientific community. EVs are bioavailable, bio compatible and resistant to RNases and proteases 93, 94 . These character istics make EVs ideal vehicles for the delivery of drugs, proteins, mi RNAs, silencing RNA (siRNA) and other molecules that would otherwise be rapidly degraded. EVs provide opportunities to deliver tissue targeted siRNA and miRs to regulate gene expression within target cells. Studies suggest that the liver is a primary site of EV uptake after intravenous delivery 45 , and experimental evidence has shown the potential use of EVs (especially the exosome subfraction) in delivering targeted RNAbased therapies in the context of liver diseases 45, 95 . Our group found that EVs can efficiently deliver a miR155 mimic or inhibitor to macrophages and hepatocytes both in vitro and in vivo 45, 95 . miR155 was previously shown to be an important mediator of liver inflammation in alcoholic hepatitis 96 . Thus, EVs derived from B cells, which harbour very low levels of endogenous miR155, were used to introduce an exogenous miR155 synthetic mimic and a miR155 inhibitor to RAW macro phages. The transferred miR inhibitor and mimic were both active and delivery of the miR155 inhibitor to RAW macrophages induced functional knockdown of TNF protein production by >50% 95 . In vivo, EVs successfully delivered an exogenous miR155 mimic to the liver and isolated hepatocytes in mir-155knockout mice 45, 95 . Exosomemediated delivery of RNAi is shown in FIG. 5 .
EVbased delivery methods for targeting different pathways involved in liver diseases are faced with several remaining challenges. First, before EVs can be used as therapy in humans, standardization and quality control of EVs will have to adhere to industry and/or regulator standards. Together with the cost of largescale produc tion of EVs, this standards issue represents a substantial challenge 2 . Second, because EV contents vary based on the type and state of parental cells 17 , the type of EV selec tion for delivery will be critical and should be selected based on the type of recipient cells and the target mol ecule. Third, although clinical trials have demonstrated that autologous EVs are welltolerated after repetitive administration 97 , the clinical therapeutic benefit of EVbased or exosomebased therapy in specific liver diseases awaits randomized controlled clinical trials.
The relevance of EVmediated signalling in the initi ation and progression of liver disease renders EVs a unique class of therapeutics targets. Different possibil ities in the clinical setting, although still largely theor etical, include interruption of EVmediated crosstalk between cells in the diseased liver. Our group showed that EVs have pivotal roles in an alternative route of HCV cellular transmission and possibly resistance cases of HCV 46 . EV removal from the circulation or inhibition of EV uptake by target recipient cells could be attractive therapeutic options in mitigating HCV transmission via EVs. EVs can be depleted from the circu lation using approaches similar to the removal of circulating anti bodies by extracorporeal dialysis utilized in autoimmune diseases 98 . In principal, this approach could be tailored for other liver diseases in which exosomes mediate deleteri ous paracrine effects. Inhibition of EV uptake is another approach that can be achieved by administration of PPIs 99 . Administration of a PPI effectively interfered with exosome uptake and prevented transmission of EVmediated HCV infection in vitro in Huh7.5 cells 46 . However, the high concentration of PPIs needed in vivo to inhibit EV uptake is a major limitation.
Studies published in the past few years indicate the involvement of EVs in repairing tissue and organ damage, which can partially explain the paracrine effects reported in stem cell therapies 100, 101 . The content of EVs can elicit cell recruitment, differentiation and prolifer ation 101 . MSCderived EVs promote hepatic regen eration in DILI animal models by inducing the IL6-STAT3 pathway and cell cycle progression 100 . In a mouse model of liver fibrosis induced by carbon tetrachloride, EVs derived from human 
Recipient cell
Clathrin-mediated endocytosis CD40L a c b umbilical cord MSCs attenuated liver fibrosis, as indicated by reduced surface fibrous capsules, reduced production of collagen type I and type III, reduced serum levels of transforming growth factor β and improved serum AST level 102 . The use of stemcellderived EVs instead of stem cell engraftment might open new perspectives for hepatic regenerative therapies. This approach would be beneficial from different perspectives. First, using EVs derived from stem cells instead of the cells themselves would remove concerns about aberrant stem cell differentiation, high immune reaction risks and risk of carcinogenesis 103, 104 . Second, immunosuppressive effects associated with certain types of EVs could support liver tissue regener ation 105 . Third, EVs and exosomes could be isolated from the blood and could be stored while maintaining their biological properties for years 104 , facilitating their use for liver regeneration at later timepoints. Although EVs offer hope for circumventing the complications associ ated with the use of viable cells in regenerative medicine, further meticu lous investigations are warranted to study the pro carcinogenic and anticarcinogenic properties reported for MSCderived EVs 28 .
Conclusions
EVs contain various biological macromolecules, includ ing proteins, genetic material and lipids, and have pivotal roles in conveying information between different cell types in the liver. EVs can alter function and activate dif ferent pathways in recipient cells, which then contribute to the initiation, progression and pathogenesis of different liver diseases. Circulating EVs are emerging as potential biomarkers of liver disease and in monitoring responses to treatment. EVs could be used for liver disease modifi cation or liver regeneration, and exploiting the inherent ability of EVs to deliver nucleic acids and other drug cargoes to cells in the liver might see EVs emerge as a novel therapeutic approach. Potential projections of the field and future directions are described in BOX 2.
